BridgeBio Pharma (BBIO) Long-Term Investments (2018 - 2026)

BridgeBio Pharma (BBIO) has 7 years of Long-Term Investments data on file, last reported at $61.5 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments fell 52.0% year-over-year to $61.5 million; the trailing twelve-month figure through Mar 2026 stood at $61.5 million (down 52.0% YoY), and the FY2025 full-year result was $80.0 million, down 44.37% from the prior year.
• Long-Term Investments slipped to $61.5 million in Q1 2026, from $80.0 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $160.4 million in Q3 2024 to a low of $61.5 million in Q1 2026.
• A 3-year average of $111.4 million and a median of $112.5 million in 2024 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments decreased 7.7% in 2025 and slumped 52.0% in 2026, its largest moves.
• Tracing BBIO's Long-Term Investments over 3 years: stood at $143.7 million in 2024, then sank by 44.37% to $80.0 million in 2025, then decreased by 23.06% to $61.5 million in 2026.
• Business Quant data shows BBIO's Long-Term Investments at $61.5 million in Q1 2026, $80.0 million in Q4 2025, and $92.2 million in Q3 2025.